|
1
|
Bartram CR, de Klein A, Hagemeijer A, van
Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G,
Ferguson-Smith MA, Davies T, Stone M, et al: Translocation of c-ab1
oncogene correlates with the presence of a Philadelphia chromosome
in chronic myelocytic leukaemia. Nature. 306:277–280. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deininger MW: Milestones and monitoring in
patients with CML treated with imatinib. Hematology Am Soc Hematol
Educ Program. 419–426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quintás-Cardama A, Cortes JE and
Kantarjian HM: Early cytogenetic and molecular response during
first-line treatment of chronic myeloid leukemia in chronic phase:
Long-term implications. Cancer. 117:5261–5270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hochhaus A, Larson RA, Guilhot F, Radich
JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F,
Fujihara S, et al: Long-term outcomes of imatinib treatment for
chronic myeloid leukemia. N Engl J Med. 376:917–927. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bixby D and Talpaz M: Mechanisms of
resistance to tyrosine kinase inhibitors in chronic myeloid
leukemia and recent therapeutic strategies to overcome resistance.
Hematology. Hematology. Am Soc Hematol Educ Program. 461–476. 2009.
View Article : Google Scholar
|
|
6
|
Weisberg E and Griffin JD: Mechanism of
resistance to the ABL tyrosine kinase inhibitor STI571 in
BCR/ABL-transformed hematopoietic cell lines. Blood. 95:3498–3505.
2000.PubMed/NCBI
|
|
7
|
le Coutre P, Tassi E, Varella-Garcia M,
Barni R, Mologni L, Cabrita G, Marchesi E, Supino R and
Gambacorti-Passerini C: Induction of resistance to the Abelson
inhibitor STI571 in human leukemic cells through gene
amplification. Blood. 95:1758–1766. 2000.PubMed/NCBI
|
|
8
|
Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571
cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 293:876–880. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alves R, Fonseca AR, Goncalves AC,
Ferreira-Teixeira M, Lima J, Abrantes AM, Alves V, Rodrigues-Santos
P, Jorge L, Matoso E, et al: Drug transporters play a key role in
the complex process of Imatinib resistance in vitro. Leuk Res.
39:355–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gambacorti-Passerini C, Zucchetti M, Russo
D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli
P, Pogliani E, et al: Alpha1 acid glycoprotein binds to imatinib
(STI571) and substantially alters its pharmacokinetics in chronic
myeloid leukemia patients. Clin Cancer Res. 9:625–632.
2003.PubMed/NCBI
|
|
11
|
Bozkurt S, Özkan T, Özmen F, Baran Y,
Sunguroğlu A and Kansu E: The roles of epigenetic modifications of
proapoptotic BID and BIM genes in imatinib-resistant chronic
myeloid leukemia cells. Hematology. 18:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hentschel J, Rubio I, Eberhart M, Hipler
C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A
and von Eggeling F: BCR-ABL- and Ras-independent activation of Raf
as a novel mechanism of Imatinib resistance in CML. Int J Oncol.
39:585–591. 2011.PubMed/NCBI
|
|
13
|
Zhong Z, Cao Y, Yang S and Zhang S:
Overexpression of RRM2 in gastric cancer cell promotes their
invasiveness via AKT/NF-κB signaling pathway. Pharmazie.
71:280–284. 2016.PubMed/NCBI
|
|
14
|
Grolmusz VK, Karászi K, Micsik T, Tóth EA,
Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, et al:
Cell cycle dependent RRM2 may serve as proliferation marker and
pharmaceutical target in adrenocortical cancer. Am J Cancer Res.
6:2041–2053. 2016.PubMed/NCBI
|
|
15
|
Wang L, Meng L, Wang XW, Ma GY and Chen
JH: Expression of RRM1 and RRM2 as a novel prognostic marker in
advanced non-small cell lung cancer receiving chemotherapy. Tumour
Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah KN, Mehta KR, Peterson D, Evangelista
M, Livesey JC and Faridi JS: AKT-induced tamoxifen resistance is
overturned by RRM2 inhibition. Mol Cancer Res. 12:394–407. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tu M, Li H, Lv N, Xi C, Lu Z, Wei J, Chen
J, Guo F, Jiang K, Song G, et al: Vasohibin 2 reduces
chemosensitivity to gemcitabine in pancreatic cancer cells via Jun
proto-oncogene dependent transactivation of ribonucleotide
reductase regulatory subunit M2. Mol Cancer. 16:662017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura Y, Kasamatsu A, Nakashima D,
Yamatoji M, Minakawa Y, Koike K, Fushimi K, Higo M, Endo-Sakamoto
Y, Shiiba M, et al: ARNT2 regulates tumoral growth in oral squamous
cell carcinoma. J Cancer. 7:702–710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joha S, Dauphin V, Leprêtre F, Corm S,
Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V,
Idziorek T, et al: Genomic characterization of Imatinib resistance
in CD34+ cell populations from chronic myeloid leukaemia
patients. Leuk Res. 35:448–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun H, Yang B, Zhang H, Song J, Zhang Y,
Xing J, Yang Z, Wei C, Xu T, Yu Z, et al: RRM2 is a potential
prognostic biomarker with functional significance in glioma. Int J
Biol Sci. 15:533–543. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
An C, Guo H, Wen XM, Tang CY, Yang J, Zhu
XW, Yin JY, Liu Q, Ma JC, Deng ZQ, et al: Clinical significance of
reduced SFRP1 expression in acute myeloid leukemia. Leuk Lymphoma.
56:2056–2060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni M, Rui Y, Chen Q, Wang Y and Li G:
Effect of growth differentiation factor 7 on tenogenic
differentiation of bone marrow mesenchymal stem cells of rat in
vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 25:1103–1109.
2011.(In Chinese). PubMed/NCBI
|
|
23
|
Weich N, Ferri C, Moiraghi B, Bengió R,
Giere I, Pavlovsky C, Larripa IB and Fundia AF: GSTM1 and GSTP1,
but not GSTT1 genetic polymorphisms are associated with chronic
myeloid leukemia risk and treatment response. Cancer Epidemiol.
44:16–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Čokić VP, Mojsilović S, Jauković A,
Kraguljac-Kurtović N, Mojsilović S, Šefer D, Mitrović Ajtić O,
Milošević V, Bogdanović A, Đikić D, et al: Gene expression profile
of circulating CD34(+) cells and granulocytes in chronic myeloid
leukemia. Blood Cells Mol Dis. 55:373–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rahman MA, Amin AR, Wang D, Koenig L,
Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG and Shin DM:
RRM2 regulates Bcl-2 in head and neck and lung cancers: A potential
target for cancer therapy. Clin Cancer Res. 19:3416–3428. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jordheim LP, Sève P, Trédan O and Dumontet
C: The ribonucleotide reductase large subunit (RRM1) as a
predictive factor in patients with cancer. Lancet Oncol.
12:693–702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engström Y, Eriksson S, Jildevik I, Skog
S, Thelander L and Tribukait B: Cell cycle-dependent expression of
mammalian ribonucleotide reductase. Differential regulation of the
two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
|
|
29
|
Liang WH, Li N, Yuan ZQ, Qian XL and Wang
ZH: DSCAM-AS1 promotes tumor growth of breast cancer by reducing
miR-204-5p and up-regulating RRM2. Mol Carcinog. 58:461–473. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang W, Tong JH, Chan AW, Zhao J, Wang S,
Dong Y, Sin FM, Yeung S, Cheng AS, Yu J and To K: Targeting
ribonucleotide reductase M2 subunit by small interfering RNA exerts
anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep.
31:2579–2586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Zhan T, Ke T, Huang X, Ke D, Wang
Q and Li H: Increased expression of RRM2 by human papillomavirus E7
oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer.
110:1034–1044. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li C, Zheng J, Chen S, Huang B, Li G, Feng
Z, Wang J and Xu S: RRM2 promotes the progression of human
glioblastoma. J Cell Physiol. 233:6759–6767. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rahman MA, Amin AR, Wang X, Zuckerman JE,
Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, et al:
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses
head and neck tumor growth. J Control Release. 159:384–392. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang L, Zhao S, Frasor JM and Dai Y: An
integrated bioinformatics approach identifies elevated cyclin E2
expression and E2F activity as distinct features of tamoxifen
resistant breast tumors. PLoS One. 6:e222742011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
|
|
38
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singh N, Tripathi AK, Sahu DK, Mishra A,
Linan M, Argente B, Varkey J, Parida N, Chowdhry R, Shyam H, et al:
Differential genomics and transcriptomics between tyrosine kinase
inhibitor-sensitive and -resistant BCR-ABL-dependent chronic
myeloid leukemia. Oncotarget. 9:30385–30418. 2018. View Article : Google Scholar : PubMed/NCBI
|
